¶ DCAF17 — DDB1 and CUL4 Associated Factor 17
DCAF17 (DDB1 and CUL4 Associated Factor 17) encodes a substrate receptor component of the CUL4-DDB1 ubiquitin ligase complex. This E3 ubiquitin ligase complex targets specific proteins for degradation, playing critical roles in various cellular processes including DNA repair, cell cycle regulation, transcription, ciliary function, and neuronal homeostasis.
DCAF17 is notably expressed in endocrine tissues and the brain, where pathogenic variants cause Woodhouse-Sakati syndrome (WSS), a rare autosomal recessive disorder characterized by progressive neurodegeneration, hypogonadism, diabetes mellitus, and hearing loss. The gene's role in the CUL4-DDB1 ubiquitin ligase pathway makes it an important player in cellular protein homeostasis and stress response.
[^2]
[^5]
[^6]
| Gene Symbol | DCAF17 |
|---|
| Full Name | DDB1 and CUL4 Associated Factor 17 |
|---|
| Chromosomal Location | 2q31.1 |
|---|
| NCBI Gene ID | 27076 |
|---|
| OMIM | 615911 |
|---|
| Ensembl ID | ENSG00000056678 |
|---|
| UniProt ID | Q9Y5R6 |
|---|
| Associated Diseases | Woodhouse-Sakati Syndrome, Hypogonadism, Neurodegeneration |
|---|
¶ Gene Structure and Evolution
The DCAF17 gene is located on chromosome 2q31.1 and consists of 10 exons encoding a protein of 459 amino acids. The gene spans approximately 25 kb and is transcribed in the centromere-to-telomere direction. Multiple transcript variants have been described, though the predominant isoform is widely expressed.
DCAF17 belongs to the DCAF (DDB1-CUL4 Associated Factor) family, which comprises over 40 members in humans. These proteins serve as substrate receptors for the CUL4-DDB1 E3 ubiquitin ligase complex. DCAF17 is evolutionarily conserved, with orthologs in vertebrates and invertebrates, reflecting its essential cellular functions.
¶ Protein Structure and Function
¶ Domain Architecture
The DCAF17 protein contains several key structural features:
- DWD box: The "DDB1-WD40" motif is required for interaction with DDB1
- H-box: A conserved histidine-containing motif involved in substrate recognition
- C-terminal domain: Mediates dimerization and complex assembly
- Nuclear localization signals: Multiple NLS sequences for nuclear targeting
DCAF17 functions as a substrate receptor within the CUL4-DDB1 E3 ubiquitin ligase complex:
DCAF17 → DDB1 → CUL4A/B → ROC1 → Ubiquitination
↓
Target Protein Degradation
This complex catalyzes the transfer of ubiquitin to substrate proteins, targeting them for proteasomal degradation. The specificity of ubiquitination is determined by the DCAF substrate receptor.
Known and proposed substrates of DCAF17 include:
- Transcription factors: Proteins involved in gene regulation
- Cell cycle regulators: Cyclins and CDK inhibitors
- DNA repair proteins: Components of the DNA damage response
- Ciliary proteins: Hedgehog signaling components
DCAF17 shows high expression in:
- Brain: Particularly in the hypothalamus, basal ganglia, and cerebellum
- Testis and ovaries: Reproductive endocrine tissues
- Pancreas: Beta cells and endocrine islets
- Liver: Hepatocytes
- Muscle: Skeletal muscle
The widespread expression explains the multi-system involvement in Woodhouse-Sakati syndrome.
DCAF17 localizes primarily to the:
- Nucleus: Nuclear localization for transcription regulation
- Cytoplasm: Cytosolic fraction for protein degradation
- Ciliary basal body: For ciliary function
DCAF17 recruits specific substrates for ubiquitination:
- Substrate recognition: Via protein-protein interaction domains
- Polyubiquitin chain formation: K48-linked chains for proteasomal degradation
- Quality control: Degradation of misfolded or damaged proteins
This function is critical for cellular protein homeostasis.
DCAF17 modulates gene expression through:
- Targeting transcriptional repressors: Promoting their degradation
- Chromatin remodeling: Influencing epigenetic modifiers
- Hormone signaling: Integrating endocrine signals with transcription
DCAF17 deficiency leads to dysregulation of genes involved in development and metabolism.
DCAF17 plays a role in ciliogenesis:
- Basal body recruitment: Essential for cilia formation
- Hedgehog signaling: Regulates GLI protein processing
- Sonic hedgehog pathway: Critical for developmental patterning
This function explains some of the developmental abnormalities in WSS.
The CUL4-DDB1-DCAF17 complex participates in DNA repair:
- Repair protein turnover: Controls levels of repair factors
- Cell cycle checkpoints: Regulates checkpoint proteins
- Genomic stability: Maintains genome integrity
Defects in this pathway may contribute to neurodegeneration.
Biallelic mutations in DCAF17 cause Woodhouse-Sakati syndrome (WSS), a rare autosomal recessive disorder characterized by:
Endocrine Features:
- Hypogonadism: Primary gonadal failure, often presenting as delayed puberty
- Diabetes mellitus: Type 2 diabetes developing in adulthood
- Hypothyroidism: Occasional thyroid dysfunction
- Growth hormone deficiency: Short stature in some patients
Neurological Features:
- Progressive dystonia: Early-onset, progressive movement disorder
- Parkinsonism: Bradykinesia, rigidity, tremor
- Cognitive decline: Progressive intellectual disability
- Seizures: Some patients develop epilepsy
Additional Features:
- Deafness: Sensorineural hearing loss
- Visual impairment: Optic atrophy in some cases
- Facial dysmorphism: Subtle facial features
- Skeletal abnormalities: Scoliosis, contractures
DCAF17 variants have been associated with:
- Hereditary spastic paraplegia: Pure and complex forms
- Ataxia: Cerebellar ataxia with or without neuropathy
- Cognitive impairment: Isolated intellectual disability
While not directly causative, DCAF17 dysregulation has been observed in:
- Breast cancer: Altered expression in tumor samples
- Prostate cancer: Potential role in tumor progression
- Hematological malignancies: Some leukemias show DCAF17 changes
The pathogenesis of WSS involves multiple mechanisms:
- Protein homeostasis disruption: Impaired ubiquitination of key substrates
- Transcription dysregulation: Altered gene expression patterns
- Ciliary dysfunction: Abnormal hedgehog signaling
- Endocrine dysfunction: Impaired hormone signaling pathways
- DNA damage accumulation: Genomic instability
DCAF17 deficiency leads to:
- Neuronal dysfunction: Impaired neuronal survival pathways
- Endocrine cell failure: Beta cell and gonadal cell death
- Accumulation of toxic proteins: Neurodegeneration
- Oxidative stress: Increased reactive oxygen species
Mouse models of DCAF17 deficiency show:
- Neurological phenotypes: Movement abnormalities
- Endocrine dysfunction: Diabetes and infertility
- Premature aging: Accelerated aging features
- Cellular pathology: Accumulation of damaged proteins
Diagnosis is confirmed by molecular testing:
- Sequencing: Targeted panel or whole exome sequencing
- Deletion/duplication analysis: Detects copy number variants
- Family studies: Carrier testing for relatives
Diagnosis is based on:
- Clinical features: At least two major features (dystonia, hypogonadism, diabetes, hearing loss)
- Family history: Autosomal recessive inheritance pattern
- Genetic confirmation: Biallelic pathogenic DCAF17 variants
WSS should be distinguished from:
- NBIA disorders: PKAN, PLAN, FA2H
- Mitochondrial disorders: Leigh syndrome, MELAS
- Other ubiquitinopathy: Hereditary spastic paraplegias
- Endocrine disorders: Isolated hypogonadism, diabetes
Management is multidisciplinary:
Neurological Care:
- Movement disorder treatment: Dopamine agonists, botulinum toxin
- Seizure control: Antiepileptic medications
- Physical therapy: Mobility and gait training
Endocrine Care:
- Hormone replacement: Testosterone/estrogen therapy
- Diabetes management: Standard glycemic control
- Thyroid replacement: As needed
Supportive Care:
- Hearing aids: For sensorineural hearing loss
- Vision support: Low vision aids
- Developmental services: Early intervention programs
Emerging treatments include:
- Gene therapy: AAV-mediated DCAF17 delivery
- Small molecule correctors: Pharmacological chaperones
- Antioxidant therapy: Mitochondrial protectants
- Cell therapy: Stem cell approaches
Patients require lifelong monitoring:
- Regular endocrine evaluation: Hormone levels, glucose
- Neurological assessments: Movement disorder severity
- Hearing and vision: Annual audiology and ophthalmology
- Quality of life: Psychological support
WSS follows autosomal recessive inheritance:
- Both alleles must be mutated for disease expression
- Parents are carriers with one mutant allele
- 25% risk for affected children in each pregnancy
Pathogenic variants include:
- Nonsense mutations: Premature stop codons (most common)
- Missense mutations: Amino acid substitutions
- Frameshift insertions/deletions: Reading frame shifts
- Splice site mutations: Altered RNA processing
- Large deletions: Genomic rearrangements
Common mutations show population-specific patterns.
- General population: Very rare (<1:200,000)
- Consanguineous populations: Higher carrier rates
- Founder mutations: Identified in specific ethnic groups
WSS is progressive but variable:
- Childhood: Usually normal early development
- Adolescence: Onset of endocrine dysfunction
- Early adulthood: Progressive neurological symptoms
- Middle age: Significant disability in many patients
Most patients have normal or near-normal life expectancy:
- Complications: Diabetes, infections, aspiration
- Quality of life: Varies with disease severity
- Long-term outlook: Improving with better care
Key research priorities:
- Substrate identification: Complete DCAF17 substrate repertoire
- Mechanism of neurodegeneration: How ubiquitin dysfunction causes neuronal loss
- Therapeutic targets: Best molecular targets for intervention
- Biomarkers: Disease progression markers
Current research focus:
- Natural history studies: Longitudinal disease progression
- Biomarker development: Clinical outcome measures
- Clinical trial readiness: Endpoint validation
Promising approaches:
- Gene replacement: AAV vectors for brain delivery
- Substrate stabilization: Blocking ubiquitination of key targets
- Symptomatic treatment: Improved movement disorder therapies
DCAF17 functions within a well-characterized pathway:
Substrate + Ubiquitin → DCAF17-DDB1 → CUL4-ROC1 → Proteasome
↓
Protein Degradation
This pathway regulates numerous cellular processes through controlled protein turnover.
DCAF17 modulates hedgehog signaling:
- GLI processing: Controls GLI transcription factor processing
- Smoothened regulation: Indirect effects on hedgehog reception
- Developmental patterning: Critical for embryonic development
Dysregulation leads to developmental abnormalities and possibly cancer.
DCAF17 integrates with endocrine pathways:
- Insulin signaling: Regulates insulin receptor substrate degradation
- Sex hormone pathways: Modulates androgen and estrogen receptor turnover
- Thyroid hormone: Influences thyroid receptor availability
These interactions explain the endocrine phenotype in WSS.
DCAF17 maintains protein homeostasis:
- Misfolded protein clearance: Targeted degradation of abnormal proteins
- Stoichiometric regulation: Balancing protein complex subunits
- Stress response: Managing cellular stress conditions
Loss of these functions leads to toxic protein accumulation.
DCAF17 affects cellular metabolism:
- Mitochondrial function: Regulates mitochondrial protein turnover
- Lipid metabolism: Controls lipid-related transcription factors
- Glucose homeostasis: Insulin signaling pathway modulation
The metabolic dysfunction in WSS reflects these roles.
DCAF17 participates in stress responses:
- DNA damage response: Regulates repair protein levels
- Oxidative stress: Manages antioxidant gene expression
- Heat shock response: Controls heat shock protein turnover
Clinical features develop at different ages:
- Infancy: Usually normal
- Childhood: May show growth retardation
- Adolescence: Hypogonadism becomes apparent
- Young adulthood: Diabetes, neurological symptoms
The progressive nature reflects ongoing neurodegeneration.
Key findings include:
- Dystonia: Limb and truncal, often severe
- Parkinsonism: Bradykinesia, rigidity
- Cerebellar signs: Ataxia, dysmetria
- Cognitive impairment: Variable degrees
Characteristic abnormalities:
- Endocrine: Low testosterone/estradiol, elevated LH/FSH
- Metabolic: Impaired glucose tolerance, elevated HbA1c
- Imaging: T2 hyperintensities in basal ganglia
Woodhouse-Sakati syndrome is rare:
- Estimated prevalence: <1:1,000,000
- Geographic distribution: Worldwide, founder mutations
- Ethnic clustering: Higher in consanguineous populations
- Carrier frequency: Very low in general population
- Founder mutations: Documented in Middle Eastern populations
- Consanguinity: Common in affected families
Healthcare impact includes:
- Diagnostic delay: Often misdiagnosed
- Specialized care: Requires multiple specialists
- Economic burden: Significant healthcare costs
Research uses multiple models:
- Mouse models: Knockout and conditional mutants
- Zebrafish: Morphants for developmental studies
- Cell culture: Neuronal and endocrine cell lines
- Organoids: Brain and pituitary organoids
DCAF17 orthologs:
- Vertebrate conservation: Highly conserved
- Invertebrate orthologs: Present in C. elegans, Drosophila
- Functional conservation: Partial functional conservation
Challenges include:
- Diagnostic expertise: Limited specialist availability
- Treatment access: Experimental therapies unavailable
- Genetic counseling: Important for family planning
Resources for patients:
- Support groups: Rare disease organizations
- Research networks: International collaboration
- Clinical registries: Patient data collection
DCAF17 itself has no enzymatic activity but:
- Scaffold function: Assembles ubiquitin ligase complexes
- Substrate recruitment: Directs specific proteins for degradation
- Allosteric regulation: May influence CUL4 activity
Key interaction partners:
| Partner |
Function |
Pathway |
| DDB1 |
Scaffold |
Ubiquitination |
| CUL4A/B |
E3 ligase core |
Ubiquitination |
| ROC1 |
E2 recruitment |
Ubiquitination |
| GLI proteins |
Substrate |
Hedgehog |
| p53 |
Substrate |
DNA damage |
DCAF17 undergoes regulation by:
- Phosphorylation: Serine/threonine kinases modulate its activity
- Sumoylation: Affects nuclear localization
- Acetylation: Regulates protein stability
In the brain, DCAF17 is highly expressed in:
- Hypothalamus: Neuroendocrine control
- Basal ganglia: Motor control circuits
- Cerebellum: Coordination and balance
- Cortex: Cognitive processing
This pattern explains the movement and cognitive phenotype in WSS.
DCAF17 also functions in glial cells:
- Astrocytes: Metabolic support
- Oligodendrocytes: Myelin maintenance
- Microglia: Immune surveillance
Glial dysfunction may contribute to neurodegeneration.
At synapses, DCAF17 regulates:
- Postsynaptic density: Protein composition
- Receptor turnover: NMDA and AMPA receptor levels
- Synaptic plasticity: Learning and memory mechanisms
Viral vector approaches being developed:
- AAV vectors: Brain-penetrant serotypes
- Non-viral delivery: Lipid nanoparticles
- CRISPR editing: Precise mutation correction
- mRNA delivery: Transient expression
Pharmacological approaches include:
- Proteostasis modulators: Enhanced autophagy
- Antioxidants: Reduce oxidative stress
- Neuroprotective agents: Promote neuronal survival
- Metabolic boosters: Improve mitochondrial function
Current treatments focus on:
- Movement disorders: Dopamine agonists, anticholinergics
- Seizures: Antiepileptic drugs
- Endocrine dysfunction: Hormone replacement
- Diabetes: Standard glycemic control